|
**Overview**: **Leukocyte Alkaline Phosphatase Score (LAP Score) Screen****Introduction**: The Leukocyte Alkaline Phosphatase Score (LAP Score) Test is a diagnostic tool designed to measure leukocyte alkaline phosphatase enzyme activity in whole blood samples, facilitating the diagnosis of leukemia or myeloproliferative disorders. Associated with chronic myelogenous leukemia or polycythemia vera, these hematologic conditions present with fatigue, splenomegaly, and severe complications like bone marrow failure if untreated, particularly in individuals with genetic predisposition or chronic inflammation. Per the 2023 American Society of Hematology guidelines, the test employs clinical pathology techniques, delivering detailed enzyme scoring over 1-2 days with reasonable sensitivity and specificity, making it a valuable tool for initial screening in clinical pathology settings. This diagnostic falls under blood disorder screening and targets individuals with systemic or hematologic symptoms, addressing the challenge of accurate enzyme classification to guide chemotherapy or phlebotomy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment, and reducing complications. Its blood-based approach ensures rapid detection.**Other Names**: LAP Score Test.**FDA Status**: FDA approved, CLIA certified for clinical pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the mid-20th century by various pathology labs, this test advanced hematology diagnostics by standardizing LAP scoring.**Purpose**: The test measures leukocyte alkaline phosphatase enzyme activity to guide leukemia or myeloproliferative disorder diagnosis, assess hematologic status, and inform treatment and prevention strategies.**Test Parameters**: Presence of leukocyte alkaline phosphatase enzyme activity, detected with reasonable specificity to indicate hematologic activity, typically observable in whole blood at altered levels during active disease, with enzyme score assessed to determine severity and distribution, providing a comprehensive profile of cellular damage that correlates with clinical presentation and guides therapeutic decisions, ensuring a detailed evaluation of affected blood components.**Pretest Condition**: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fatigue, splenomegaly, or recent hematologic symptoms.**Specimen**: Whole Blood 2-3 mL, collected using EDTA tubes, transported within 24 hours to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling in a cool environment to preserve cell integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not recommended, as freezing may degrade cells, increasing the risk of false negatives and compromising diagnostic accuracy.**Medical History**: Patients should provide details on fatigue, splenomegaly, prior blood disorders, or family history of hematologic disease, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated disease including bone marrow failure, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves blood sample processing, staining with naphthol AS-BI phosphate, and scoring under microscopy by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent therapy can affect results. Correlation with bone marrow biopsy or clinical evaluation is recommended to confirm findings.**Clinical Significance**: A positive result indicates possible leukemia or myeloproliferative disorder, necessitating further investigation like bone marrow biopsy or hematology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early stages.**Specialist Consultation**: Hematologists should be consulted for case management, treatment planning, and coordination with blood disorder programs.**Additional Supporting Tests**: Bone marrow biopsy, CBC, or BCR-ABL testing for confirmation.**Test Limitations**: The test may produce false positives in reactive conditions or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: ASH Guidelines 2023, Journal of Hematology 2024, Clinical Pathology 2025. |
